Johnson & Johnson Seeks EMA Approval to Extend AKEEGA Use for Prostate Cancer
July 3, 2025
The submission is based on results from the Phase 3 AMPLITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisone or prednisolone compared to